oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Epigenetic markers – definition and significance for early cancer detection
BlogAs a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical […]
Pilot study: Cancer screening from home is possible
Press ReleasesA large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much […]
Step USA – our virtual business trip
BlogWhat has to be considered if you want to start as a German biotech company on the American market? What are the legal bases and challenges there? We got an […]
Positive HPV test: What now?
BlogSince the beginning of 2020, when early cervical cancer screening in Germany was supplemented by a routine HPV test for women over 35, more people have been confronted with a […]
We’ve moved: More space for new challenges
BlogAt the beginning of May, things were turbulent, because we moved into our new offices and laboratories. The new location in a business park in Jena enables us to create […]
Study „OroCa-Graz“ – Study on Head-and-Neck tumors: oncgnostics GmbH cooperates with the Medical University of Graz
Press ReleasesThe biotechnology company oncgnostics GmbH is researching a method for diagnosing Head-and-Neck tumors together with the clinical department for general ENT at the Medical University of Graz as part of […]
International sales partnership with EUROIMMUN for Distribution of GynTect
Press ReleasesBiotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from […]
PCR: Certainty in the shortest possible time
BlogThe method of the PCR stands for the polymerase chain reaction. The underlying process has fundamentally changed medical and biotechnological research. It is now considered the most important laboratory method […]
Looking back on a successful year of research
Blog2020 was a challenging year – also for our company. Nevertheless, we look back on successful achievements. GynTect® convinces in test comparison In November, the journal Clinical Epigenetics published a […]
HPV Vaccination: Help against various Types of Cancer
BlogThe World Health Organization (WHO) sees an increasing HPV vaccination worldwide as a great opportunity in the fight against various types of cancer. At the organization’s annual meeting, WHO director […]